公司信息 - Alkermes plc是一家全球生物制药公司，致力于在神经科学领域开发创新药物[3] - Alkermes的联系人是Jamie Constantine，负责投资者关系[4] 财务业绩 - Alkermes plc将于2024年2月15日举行电话会议和网络直播，讨论公司2023年第四季度和年度财务业绩[1] - 可通过Alkermes官网的投资者部分访问网络直播播放器和相关幻灯片[2]

Alkermes (ALKS) 盈利预期 - Alkermes (ALKS) 预计在2023年12月报告的季度收益将同比增长，预计每股收益为0.43美元，同比增长207.1%[4] - 分析师最近对公司的盈利前景变得乐观，最准确的估计高于Zacks共识估计，显示出+8.88%的盈利预期[12] - Alkermes在过去四个季度中四次击败共识EPS估计，最近一次季度盈利超出预期45.45%[14]

Alkermes (ALKS) closed the latest trading day at $26.70, indicating a -1.26% change from the previous session's end. The stock's performance was behind the S&P 500's daily gain of 0.82%. Elsewhere, the Dow saw an upswing of 0.41%, while the tech-heavy Nasdaq appreciated by 0.95%. The drugmaker's stock has dropped by 6.69% in the past month, falling short of the Medical sector's gain of 3.2% and the S&P 500's gain of 5.59%. Analysts and investors alike will be keeping a close eye on the performance of Alkerm ...

The quest for prime biotech stocks for gains will always be relevant. Moreover, 2024 promises a surge in technology and science, positioning biotech firms at the forefront of novel medical breakthroughs. Grand View Research underscores this optimism, projecting a robust 13.96% CAGR for the biotech market from 2024 to 2030. Fueling this growth is an expanding clinical trial pipeline and robust regulatory backing for startups. Moreover, strides in DNA sequencing, mRNA, and cell-based assays signal a burgeonin ...

Alkermes (ALKS) closed at $26.94 in the latest trading session, marking a -0.41% move from the prior day. This change lagged the S&P 500's daily gain of 1.25%. On the other hand, the Dow registered a gain of 0.97%, and the technology-centric Nasdaq increased by 1.3%. Prior to today's trading, shares of the drugmaker had lost 5.65% over the past month. This has lagged the Medical sector's gain of 1.52% and the S&P 500's gain of 1.58% in that time. Analysts and investors alike will be keeping a close eye on t ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Alkermes (ALKS) , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider. This drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 30.02%. For the most recent quarter, Alkermes was ex ...

股价表现 - Alkermes (ALKS) 最新收盘价为 $27.74，较前一天下跌了 1%[1] - 近一个月来，这家制药公司的股价上涨了0.5%[2] 财务业绩预期 - 预计Alkermes将报告每股收益为 $0.42，较去年同期增长了200%[3] - 最新的共识估计预计营收为 $3.6167 亿美元，较去年同期增长了18.71%[3] 分析师预测 - 投资者应关注Alkermes的分析师预测是否有最近的变化[4] - 最近的修订往往反映了最新的短期业务趋势[4] Zacks Rank评级系统 - Zacks Rank系统从1（强热门）到5（强卖出），Alkermes目前拥有一个Zacks Rank为3（持有）[5][6] - 1股票的平均年回报率为+25%，Zacks共识每股收益预估上调了0.36%[5][6] 估值指标 - Alkermes目前的前瞻市盈率为12.31，相对于行业平均的22.09的前瞻市盈率，具有折价[7] 行业排名 - 医疗-生物医学和遗传学行业属于医疗行业，目前的Zacks行业排名为95，位于所有250多个行业的前38%[8] - Zacks行业排名通过计算各个股票的平均Zacks Rank来评估特定行业群体的活力[9]

生物技术公司投资吸引力 - 生物技术行业的公司对投资者非常有吸引力，因为它们在发布积极或消极消息后的股价会出现剧烈波动，尤其是对于小型生物技术公司[1] - 投资者寻找投资组合中一些风险较高的选择时，生物技术公司可能是一个不错的选择，因为存在巨大的上涨潜力[2] Alkermes 公司业绩 - Alkermes (ALKS)是一家位于爱尔兰都柏林的生物制药公司，其总收入较去年同期增长了51%，主要得益于其旗舰精神病药Lybalvi的盈利能力增强，销售额同比增长了87%[6] - ALKS最近宣布将其肿瘤业务拆分为Mural Oncology (NASDAQ:MURA)，现在Alkermes经营纯粹的神经科学业务[7] MacroGenics 公司业绩 - MacroGenics (MGNX)是一家拥有广泛癌症治疗药物的制药公司，其股价在过去六个月内翻了一番，Citi提升了对MacroGenics的评级，股价因其治疗前列腺癌的积极数据而上涨了13%[9] Heron Therapeutics 公司业绩 - Heron Therapeutics (HRTX)是一家生物技术公司，其产品销售总额增长了18%，净亏损减少了40%[13]

Alkermes plc (NASDAQ:ALKS) Q3 2023 Results Earnings Conference Call October 25, 2023 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President, Corporate Affairs and Investor Relations Iain Brown - Senior Vice President and Chief Financial Officer Todd Nichols - Senior Vice President and Chief Commercial Officer Craig Hopkinson - Executive Vice President, Research & Development and Chief Medical Officer Richard Pops - Chairman and Chief Executive Officer Conference Call Participants Amy Li - Jef ...

业绩总结 - 公司第三季度2023年总收入为380.9百万美元，较去年同期增长51%[6] - VIVITROL®净销售额为99.3百万美元，较去年同期增长3%[7] - ARISTADA®净销售额为81.8百万美元，较去年同期增长8%[7] - LYBALVI®净销售额为50.7百万美元，较去年同期增长87%[7] - 公司预计2023年净销售额将在1550 - 1680百万美元之间[9] - 预计2023年VIVITROL®净销售额将在380 - 410百万美元之间[9] - 预计2023年ARISTADA®净销售额将在315 - 345百万美元之间[9] - 预计2023年LYBALVI®净销售额将在180 - 205百万美元之间[9] - 公司预计2023年的非GAAP净收入为250百万美元[29] - 公司2023年的每股收益预计为1.46美元[29] 新产品和新技术研发 - ALKS 2680是一种口服的奥雷昔康2受体激动剂，用于治疗嗜睡症[18] - ALKS 2680相较于奥雷昔A具有超过10倍的高效性[18] - ALKS 2680在小鼠嗜睡症模型中显示出剂量依赖的改善[18] - ALKS 2680在健康志愿者中表现出良好的耐受性[20] - ALKS 2680的药代动力学特性支持每日一次的口服给药[21] - NT1患者中，ALKS 2680显著改善了睡眠潜伏期[25] - NT1患者中，ALKS 2680在3mg和8mg之间显示出治疗剂量[26] - ALKS 2680在健康志愿者中提高了警觉性的客观和主观指标[27]